Gossamer Bio, Inc. GOSS R2K
Healthcare · Biotechnology · United States
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
READ MORE ›$0.23
-79.19% 1Y
Market & Price
Market Cap
$54.19M
Current Price
$0.23
High / Low (52W)
$3.79 / $0.19
Beta
2.15
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$-0.69
Price to Book
-0.34
P/S
0.98
EV/EBITDA
-0.92
Dividend Yield
-
Profitability & Returns
ROCE
-146.55%
ROE
-
ROA
-52.29%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.20
EPS (TTM)
$-0.79
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
1.92
Current Ratio
2.20
Debt
$202.93M
Total Assets
$172.25M
Current Assets
$167.64M
Working Capital
$104.21M
Ownership
Promoter Holding
3.53%
Chg in Prom Hold
-
FII / Inst Holding
72.76%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$157.91M
Total Revenue (TTM)
$55.54M
EBITDA
$-171.29M
Free Cash Flow
$-97.25M
Operating Cash Flow
$-170.26M
Shares Outstanding
234.70M
Gross Margin
100.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
8.58%
Revenue (YoY)
71.50%
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Trading 93.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GOSS Gossamer Bio, Inc. R2K | 0.23 | - | $54.19M | - | -146.55% | - | - | 8.58% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 95.84M | - | - | 9.89M | 11.49M | 13.29M | 13.80M | 16.95M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 46.70M | 50.25M | 54.93M | 59.84M | 61.82M |
| Operating Income | -26.13M | -33.04M | -50.02M | -39.81M | -34.02M | -46.35M | -49.99M | -55.79M | -54.97M | -65.34M | -53.57M | -53.20M | -55.60M | -55.66M | -54.34M | -53.87M | -56.02M | -47.94M | -46.30M | -40.49M | -41.96M | 52.09M | - | - | -36.81M | -38.77M | -41.64M | -46.04M | -44.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.55M | -35.32M | -45.25M | -44.35M | -43.68M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.75M | 2.74M | 2.75M | 2.75M | 2.75M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -36.64M | -38.27M | -48.22M | -47.33M | -46.66M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.13M | -2.41M | - | 0 | 0 | -88.00K | - |
| Net Income | -26.04M | -32.73M | -49.41M | -38.79M | -32.61M | -44.50M | -48.50M | -54.70M | -54.07M | -66.87M | -57.81M | -57.64M | -59.83M | -60.25M | -57.78M | -56.47M | -59.36M | -49.16M | -42.50M | -40.01M | -41.93M | 49.23M | - | - | -36.64M | -38.27M | -48.22M | -47.24M | -46.66M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.87 | -1.00 | -0.80 | -0.78 | -0.80 | -0.80 | -0.76 | -0.74 | -0.65 | -0.52 | -0.45 | -0.21 | -0.19 | 0.22 | - | - | -0.16 | -0.17 | -0.21 | -0.21 | -0.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 114.70M | 48.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 218.53M | 173.76M | 174.62M | 211.72M |
| Operating Income | -6.65M | -148.99M | -186.14M | -233.96M | - | -218.53M | -173.76M | -59.92M | -163.25M |
| EBITDA | - | - | - | - | - | -211.07M | -161.92M | -39.97M | -158.47M |
| Interest Expense | - | - | - | - | - | 13.88M | 13.51M | 11.52M | 10.99M |
| Pretax Income | - | - | - | - | - | -229.38M | -179.82M | -55.63M | -170.46M |
| Tax Provision | - | - | - | - | - | 0 | 0 | 893.00K | -88.00K |
| Net Income | -6.77M | -146.97M | -180.31M | -243.36M | - | -229.38M | -179.82M | -56.53M | -170.37M |
| Diluted EPS | - | - | -3.29 | -3.55 | - | -2.71 | -1.18 | -0.25 | -0.75 |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 71.50% |
Compounded Profit Growth
| 5 Years: | 8.58% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -79.19% |
| 6 Months: | -92.94% |
| 3 Months: | -45.65% |
| 1 Month: | -34.00% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 239.42M | 426.60M | 539.43M | - | 272.45M | 311.92M | 315.29M | 172.25M |
| Current Assets | - | - | - | - | - | - | 261.88M | 306.52M | 309.89M | 167.64M |
| Cash & Equivalents | - | - | 105.22M | 135.03M | 486.06M | - | 111.97M | 32.11M | 46.07M | 37.73M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | 0 | 5.34M | 12.23M |
| Total Liabilities | - | - | 21.12M | 74.12M | 218.75M | - | 260.37M | 249.15M | 285.80M | 295.01M |
| Current Liabilities | - | - | 20.40M | 36.92M | 38.65M | - | 49.23M | 51.60M | 45.01M | 63.44M |
| Long Term Debt | - | - | - | 28.46M | 28.74M | - | 207.70M | 197.41M | 197.52M | 198.51M |
| Total Debt | - | - | - | - | - | - | 225.74M | 212.46M | 202.88M | 202.91M |
| Total Equity | -123.00K | -6.86M | -120.07M | 352.49M | 320.68M | - | 12.08M | 62.77M | 29.49M | -122.76M |
| Shares Outstanding | - | - | - | - | - | - | 94.42M | 225.41M | 226.60M | 233.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.75M | -51.04M | -144.83M | -176.36M | - | -187.03M | -159.16M | -3.47M | -171.27M |
| Investing Cash Flow | - | -144.71M | -147.14M | 215.34M | - | -1.03M | -110.97M | 29.02M | 156.36M |
| Financing Cash Flow | 6.00M | 300.86M | 321.58M | 312.54M | - | 117.09M | 190.15M | -11.49M | 6.42M |
| Capital Expenditure | - | -3.49M | -2.97M | -1.50M | -1.62M | -475.00K | - | - | -79.00K |
| Free Cash Flow | - | -54.53M | -147.80M | -177.86M | - | -187.51M | -159.16M | -3.47M | -171.34M |
| Net Change in Cash | - | - | - | - | - | -70.98M | -79.97M | 14.07M | -8.48M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -52.2% | -336.8% |
| Net Margin % | - | - | - | - | - | - | - | -49.3% | -351.5% |
| ROE % | 98.7% | 122.4% | -51.2% | -75.9% | - | -1,899.3% | -286.5% | -191.7% | 138.8% |
| ROCE % | - | -68.0% | -47.8% | -46.7% | - | -97.9% | -66.7% | -22.2% | -150.0% |
Shareholding Pattern
Insiders
3.53%
Institutions
72.76%
Public Float
75.43%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.17% | 16.83M | $3.89M |
| 2 | Kalehua Capital Management LLC | 4.36% | 10.24M | $2.36M |
| 3 | AQR Capital Management, LLC | 4.31% | 10.13M | $2.34M |
| 4 | Vanguard Capital Management LLC | 4.00% | 9.39M | $2.17M |
| 5 | Arch Venture Management, Llc | 3.43% | 8.06M | $1.86M |
| 6 | Octagon Capital Advisors LP | 3.30% | 7.75M | $1.79M |
| 7 | Samsara BioCapital, LLC | 3.08% | 7.22M | $1.67M |
| 8 | Balyasny Asset Management LP | 2.52% | 5.92M | $1.37M |
| 9 | Acadian Asset Management. LLC | 2.25% | 5.28M | $1.22M |
| 10 | Siren, L.L.C. | 2.22% | 5.21M | $1.20M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GOSS
No recent headlines available.